Johnson & Johnson (JNJ): Capital Expenditures
$4.83B
Year ended 2025-12-28
$5.57B
Trailing 12 months to 2026-09-27
+6.4%
3-year compound annual growth
+7.6%
5-year compound annual growth
+3.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $4.83B | +9.2% | 2026-02-11, From 2024-12-30 |
| 2024-12-29 | $4.42B | -2.6% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $4.54B | +13.3% | 2026-02-11, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $4.01B | +9.8% | 2025-02-13, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $3.65B | +9.1% | 2024-02-16, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $3.35B | -4.3% | 2023-02-16, From 2019-12-30 |
| 2019-12-29 | $3.50B | -4.7% | 2022-02-17, From 2018-12-31 |
| 2018-12-30 | $3.67B | +11.9% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $3.28B | +1.6% | 2020-02-18, From 2017-01-02 |
| 2017-01-01, Fiscal 2016 | $3.23B | -6.8% | 2019-02-20, From 2016-01-04 |
| 2016-01-03, Fiscal 2015 | $3.46B | -6.8% | 2018-02-21, From 2014-12-29 |
| 2014-12-28 | $3.71B | +3.3% | 2017-02-27, From 2013-12-30 |
| 2013-12-29 | $3.60B | +22.5% | 2016-02-24, From 2012-12-31 |
| 2012-12-30 | $2.93B | +1.4% | 2015-02-24, From 2012-01-02 |
| 2012-01-01, Fiscal 2011 | $2.89B | +21.4% | 2014-02-21, From 2011-01-03 |
| 2011-01-02, Fiscal 2010 | $2.38B | +0.8% | 2013-02-22, From 2010-01-04 |
| 2010-01-03, Fiscal 2009 | $2.37B | -22.9% | 2012-02-23, From 2008-12-29 |
| 2008-12-28 | $3.07B | +4.2% | 2011-02-25, From 2007-12-31 |
| 2007-12-30 | $2.94B | n/a | 2010-03-01, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.84B | +55.0% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $1.21B | +24.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗